The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry
Autor: | Birgit E.P.J. Vriens, J. Heijnen-Mommers, Frans L. G. Erdkamp, M. de Boer, Bram Ramaekers, VC Tjan-Heijnen, Kirsten N. A. Aaldering, N.A.J.B. Peters, A.J. van de Wouw, Manuela A. Joore, J.M.G.H. van Riel, Manon J. Pepels, Tineke J. Smilde, Xavier Pouwels, S. M. E. Geurts, M.W. Dercksen |
---|---|
Přispěvatelé: | MUMC+: KIO Kemta (9), Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Interne Geneeskunde |
Rok vydání: | 2019 |
Předmět: |
Oncology
Adult medicine.medical_specialty Advanced breast MONOTHERAPY MULTICENTER MESYLATE CAPECITABINE TOXICITY 030218 nuclear medicine & medical imaging relative effectiveness 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Overall survival breast neoplasms Humans Radiology Nuclear Medicine and imaging Registries Eribulin Furans Aged Netherlands business.industry genetic matching matching Cancer Hematology General Medicine Ketones Middle Aged medicine.disease EFFICACY Cancer registry Cancer treatment Survival Rate Treatment Outcome chemistry 030220 oncology & carcinogenesis SAFETY Multivariate Analysis Female EXPANDED ACCESS PROGRAM business |
Zdroj: | Acta Oncologica, 59(1), 82-89. Routledge/Taylor & Francis Group |
ISSN: | 0284-186X |
DOI: | 10.6084/m9.figshare.9938291.v1 |
Popis: | Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013–2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described. Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7–5.5) in the eribulin group and 3.2 months (95% CI: 2.0–4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49–1.38). Median OS was 5.9 months (95% CI: 4.6–11.0) and 5.2 months (95% CI: 4.6–9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38–1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin. Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile. |
Databáze: | OpenAIRE |
Externí odkaz: |